IL8 Monitoring and Its Correlation With 251-gene Polymorphism
One hundred eighty critically ill African adult intensive care patients divided into two groups, eighty septic critically ill patients (sepsis group) while, eighty non-septic critically ill patients (SIRS) group. Admission serum IL-8 was measured in both sepsis and SIRS groups. IL-8 (-251A/T) polymorphism was detected in sepsis and SIRS groups.
Systemic Inflammatory Response Syndrome
|Study Design:||Observational Model: Case Control
Time Perspective: Prospective
|Official Title:||The Value of Admission Serum Il-8 Monitoring and the Detection of IL8 (-251 A/T) Polymorphism in Critically Ill Patients|
- Serum Interlukin-8 [ Time Frame: At intensive care admission. Patients will be followed for at least 2 weeks ] [ Designated as safety issue: Yes ]Serum level of IL-8 was determined by quantitative sandwich enzyme immunoassay (R&D Systems, Inc., Minneapolis, MN, USA) according to the manufacturer's instructions. The intensity of the colour was measured at 490 nm for IL-8.
- Interlukine-8polymorphism at 251 A/t [ Time Frame: At ICU admission. Patients will be followed for at least 2weeks. ] [ Designated as safety issue: Yes ]About 4ml blood is withdrawn in EDTA-tubes and the genomic DNA was extracted. Concentration of the extracted DNA was then measured by UV spectrophotometry at 260& 280 nm and run on agaros gel electrophoresis 2% for detection of purity. Molecular detection of the (-251 A/T) polymorphism in the IL-8gene was achieved by restriction fragment length polymorphism typing.
|Study Start Date:||November 2012|
|Study Completion Date:||February 2013|
|Primary Completion Date:||February 2013 (Final data collection date for primary outcome measure)|
Forty patients developed septic complication during ICU stay (sepsis group).
Forty patients were critically ill without evidence of infectious organism (SIRS group).
A total of one hundred eighty African patients (97men and 83 women) were included in the study. Eighty patients developed septic complication during ICU stay (sepsis group). Eighty patients were critically ill without evidence of infectious organism (SIRS group). Patients received anti-inflammatory drugs or corticosteroids before admission, who had immunosuppressive illness, who had chronic organ failure; who had received massive blood transfusion; those with radiation therapy, previous organ transplantation were excluded from the study. At admission, the patient's age, sex, height and weight were recorded. These data include the following: clinical status; sequential organ failure assessment (SOFA) score; temperature; heart rate; respiratory rate; blood pressure; central venous pressure; laboratory analysis (complete blood count, blood urea nitrogen, blood sugar, serum sodium, potassium, calcium, aspartate aminotransferase, alanine aminotransferase, prothrombin time, albumin and CRP) and arterial blood gas analysis. Routine cultures of blood, urine and suspected sites were obtained to determine the presence of infection. We attempted to maintain the patient hemoglobin level at 10-12g/dl and central venous pressure at 8-12 cmH2o. If needed, blood products, intravascular fluid replacement and inotropic and/or vasopressor agents were administered. Each day the attending physician in the ICU evaluated all the study patients for sepsis, severe sepsis, or septic shock.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01708759
|Faculty of Medicine ,Tanta University.|
|Tanta, Algharbiya, Egypt, 35217|
|Principal Investigator:||Ayman A Yousef, MD||Assistant professor os Anesthesia and ICU, Faculty of Medicine, Tanta university|